Canaccord Genuity analyst Edward Nash has maintained their bullish stance on VTYX stock, giving a Buy rating on November 8. Edward ...

Ventyx stock shows all the characteristics of a highly underappreciated issue with surprisingly valuable assets that can be ...

Sanofi will gain exclusivity rights to Ventyx Biosciences’ CNS-penetrant candidate VTX3232 as part of a $27m deal. Under the ...

VTX3232 is geared toward neuroinflammatory and neurodegenerative conditions, including Parkinson’s disease, cardiometabolic ...

Topline results from the Phase 2a trial of VTX3232 in patients with early Parkinson’s disease expected in H1 2025 Phase 2 trial of VTX3232 in subjects with obesity and cardiometabolic risk factors ...

Sanofi agreed to make a $27 million strategic investment in Ventyx Biosciences Inc. The company also agreed to grant Sanofi an exclusive right of first negotiation with respect to certain VTX3232 ...

In his iconic song The Gambler, Kenny Rogers famously sang, “Every hand’s a winner, and every hand’s a loser.” This line offers valuable wisdom for investors: no matter the strategy ...

Sanofi invests $27 million in Ventyx Biosciences at $3.8243 per share. The investment will fund VTX3232 trials for Parkinson's disease.

Nov. 6, 2024 — Sewage surveillance is emerging as a powerful tool in the fight against antimicrobial resistance with the potential to protect vulnerable communities more ... Nov. 6, 2024 ...

November 4, 2024 • How did life start on Earth? The answer is a big scientific mystery scientists are actively investigating. After talking with many scientists, host Regina G. Barber found that ...